Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Aim: Cetuximab is used for the treatment of RAS wild-type metastatic colorectal cancer patients. Standard administration schedule is once a week; however, the bioequivalence of an every-other-week (EOW) schedule was demonstrated. Methods: We compared a base case scenario of 100% weekly administration to an EOW at 50 or 100%. Medical examinations, patient management and loss of productivity were considered. Results: Base case was estimated at €100.6 million versus €92.8 million and €84.9 million of EOW 50 and 100%, which showed a cost reduction of 8 and 16%, respectively. Indirect costs accounted for 65% in both scenarios. Conclusion: The adoption of an EOW administration schedule of cetuximab reduced direct and indirect costs substantially.

Original publication

DOI

10.2217/fon-2018-0904

Type

Journal article

Journal

Future oncol

Publication Date

06/2019

Volume

15

Pages

2107 - 2112

Keywords

bi-monthly administration, budget impact, cetuximab, Antineoplastic Agents, Immunological, Cetuximab, Colorectal Neoplasms, Drug Administration Schedule, Female, Health Care Costs, Health Expenditures, Humans, Incidence, Male, Neoplasm Metastasis, Neoplasm Staging, Population Surveillance